ArticleTherapeutic advances in musculoskeletal disease2024

Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients.

Hafsah Nabi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.